

날짜: 2018년 3월 24일 (토)

장소: 부산 해운대 벡스코

연수평점: 4점

PROGRA	M	사회: 엄중섭 (부산의대)
11:30~11:50	등록	
11:50~12:50	식사	
12:50-12:55	개회 및 인사말	<b>김영철</b> (표적치료연구회 회장)
12:55-13:00	축사	이계영 (대한폐암학회 이사장)
Section 1: Detection & Management of low-frequency oncogenic drivers		<b>좌장: 이계영</b> (건국의대) <b>양세훈</b> (원광의대)
13:00~13:20	Large scale lung cancer genome projects to uncover oncogenic drivers	<b>장세진</b> (울산의대)
13:20~13:40	Practical application of NGS platforms in Korea	<b>이정은</b> (충남의대)
13:40~14:00	MET skipping mutation & amplification, B-raf, and HER2 mutation	<b>최창민</b> (울산의대)
14:00~14:20	ROS1 & RET translocation	<b>손지웅</b> (건양의대
14:20~14:40	Coffee Break	
Section2: The upcoming issues on next-generation TKIs		<b>좌장: 김영환</b> (서울의대) <b>이민기</b> (부산의대)
14:40~15:00	How to manage T790M-negative EGFR-mutant lung cancer after resistance?	<b>이승현</b> (경희의대)
15:00~15:20	what's the next upon osimertinib-resistance?	<b>장승훈</b> (한림의대)
15:20~15:40	Current status of novel ALK inhibitors following alectinib	<b>박철규</b> (전남의대)
15:40~16:00	Coffee Break	
	Section 3: Recent updates on immuno-oncology	<b>좌장: 장태원</b> (고신의대) 이 <b>재철</b> (울산의대)
16:00~16:20	Diagnostic issues for immunotherapy in Korea	<b>김완섭</b> (건국의대)
16:20~16:40	Early death problems by immune-check point inhibitors	<b>박찬권</b> (가톨릭의대)
16:40~17:00	Resistant mechanisms to immuno-oncology drugs	정치영 (대구가톨릭의대)

